FDA
-
-
-
-
-
-
-
The Biology Came First.
-
-
-
-
-
-
-
RBC Capital Starts argenx SE (ARGX) at Outperform
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on argenx SE (ARGX)
-
-
-
-
-
-
-
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
-
-
-
-
-
-
-
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
-
-
-
-
-
-
-
argenx (ARGX) and Zai Lab (ZLAB) Announce FDA Approval of VYVGART
-
-
-
-
-
-
-
argenx (ARGX) to Acquire Priority Review Voucher from FDA for $102M
-
329,909 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

